Company Analysis
Sign in

enGene Therapeutics Inc. (ENGN)

Nasdaq: ENGN · Biological Products, (No Diagnostic Substances) · Saint-Laurent, QC · filing with the SEC since 2023
Full chart Alerts Compare
Grade4.3
◀ Past 4.1● Present 3.8▶ Future 4.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$117M-112.7%
Earnings per share$2.29+56.8%
Operating cash flow-$99.2M-105.5%
Cash$50.2M-71.0%
Debtn/a
Shareholders’ equity$168M-38.5%
Shares, diluted51.1M+35.3%
Return on equity-69.9%
The recordfrom its filings
Filings in 202659
Newest filingNov 12 · 8-K
Annual reportDec 22, 2025
Quarterly reportSep 8, 2026
Next report due10-K by Jan 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Jul 2026Net income -$130MCash from operations -$103Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
22232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Sep 24, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 8, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Sep 8, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 11, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ENGN · research, not advice